I agree. Getting distracted with poor targets (even if additional money is given for them) can have bad results for an early biotech.
"First pick the low hanging fruit." Get revenues coming in and a sound financial foundation. THEN you can go after more challenging targets without incurring a high risk of bankruptcy should one or two fail.
Going for fruit too high on the tree right from the start is the overwhelming cause of failure of early biotechs.
The critical focus in the beginning should always be to prove the technology works with a simple easy target or two (and learn about the technology in the process.)
News 
Market Data 
Discover 
AI
